Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update in HIV-associated lymphoma.

Ariela Noy1

  • 1Division of Hematology, Memorial Sloan-Kettering Cancer, Weill Medical College of Cornell University, New York, New York 10021, USA. noya@mskcc.org

Current Opinion in Oncology
|August 18, 2004
PubMed
Summary

People with human immunodeficiency virus (HIV) can use many standard lymphoma treatments. Some therapies may have unique toxicities, but high-dose options show promise for difficult cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same author

Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study.

Cancers·2026
Same author

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial.

Cancers·2026

Area of Science:

  • Oncology
  • Infectious Diseases
  • Immunology

Background:

  • Human immunodeficiency virus (HIV) infection elevates the risk of developing non-Hodgkin lymphoma and Hodgkin disease.
  • Understanding lymphoma treatment in HIV-infected individuals is crucial for effective patient management.

Purpose of the Study:

  • To review recent advancements in lymphoma treatment for patients with HIV.
  • To assess the applicability and outcomes of standard lymphoma therapies in the context of HIV infection.

Main Methods:

  • Literature review of studies published within the last 18 months.
  • Analysis of treatment efficacy and toxicity in HIV-positive lymphoma patients.

Main Results:

  • Many standard lymphoma therapies are applicable to HIV-infected patients during the highly active antiretroviral therapy (HAART) era.
  • Certain treatments, like rituximab with CHOP, may present unexpected toxicities.
  • High-dose therapy is feasible and potentially curative for refractory or relapsed lymphoma in HIV-infected individuals.

Conclusions:

  • HIV-infected individuals generally benefit from standard lymphoma treatments.
  • Treatment selection requires careful consideration of potential biologic differences and specific toxicities.

Related Experiment Videos